Literature DB >> 20048705

The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility.

Bette Korber1, S Gnanakaran.   

Abstract

PURPOSE OF REVIEW: Designing an HIV vaccine capable of eliciting broadly cross-reactive neutralizing antibodies is an extraordinarily difficult challenge. Here we focus on the implications of HIV diversity for vaccine design, detailing the impact of levels of variation in epitopes of known potent neutralizing antibodies, and summarizing patterns of overall variation in regional domains within gp120. Strategies for rational vaccine design, to enhance coverage of HIV's natural diversity, are considered. RECENT
FINDINGS: Each amino acid in an envelope gp120 three-dimensional structure was grouped with its 10 nearest neighbors and classified by their natural sequence variability. Within-subtype variation is superimposed on patterns of subtype-specific variation. Regions under selection with moderate diversity are realistic vaccine targets; their variation reflects the value of escape in these regions, whereas the level of diversity is potentially approachable with a vaccine.
SUMMARY: HIV diversity is so extensive that vaccine design strategies may benefit by factoring in diversity from the earliest stages, even for vaccines that target relatively conserved regions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20048705      PMCID: PMC6426297          DOI: 10.1097/COH.0b013e32832f129e

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  25 in total

1.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Authors:  Jennifer L Kirchherr; Jennifer Hamilton; Xiaozhi Lu; S Gnanakaran; Mark Muldoon; Marcus Daniels; Webster Kasongo; Victor Chalwe; Chanda Mulenga; Lawrence Mwananyanda; Rosemary M Musonda; Xing Yuan; David C Montefiori; Bette T Korber; Barton F Haynes; Feng Gao
Journal:  Virology       Date:  2010-10-30       Impact factor: 3.616

2.  Challenges of antibody-mediated protection against HIV-1.

Authors:  George K Lewis
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

3.  HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes.

Authors:  Florencia Pereyra; David Heckerman; Jonathan M Carlson; Carl Kadie; Damien Z Soghoian; Daniel Karel; Ariel Goldenthal; Oliver B Davis; Charles E DeZiel; Tienho Lin; Jian Peng; Alicja Piechocka; Mary Carrington; Bruce D Walker
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

4.  Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.

Authors:  Peter Hraber; Bette T Korber; Alan S Lapedes; Robert T Bailer; Michael S Seaman; Hongmei Gao; Kelli M Greene; Francine McCutchan; Carolyn Williamson; Jerome H Kim; Sodsai Tovanabutra; Beatrice H Hahn; Ronald Swanstrom; Michael M Thomson; Feng Gao; Linda Harris; Elena Giorgi; Nicholas Hengartner; Tanmoy Bhattacharya; John R Mascola; David C Montefiori
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

5.  Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.

Authors:  Sandrine L Hulot; Bette Korber; Elena E Giorgi; Nathan Vandergrift; Kevin O Saunders; Harikrishnan Balachandran; Linh V Mach; Michelle A Lifton; Giuseppe Pantaleo; Jim Tartaglia; Sanjay Phogat; Bertram Jacobs; Karen Kibler; Beatriz Perdiguero; Carmen E Gomez; Mariano Esteban; Margherita Rosati; Barbara K Felber; George N Pavlakis; Robert Parks; Krissey Lloyd; Laura Sutherland; Richard Scearce; Norman L Letvin; Michael S Seaman; S Munir Alam; David Montefiori; Hua-Xin Liao; Barton F Haynes; Sampa Santra
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

6.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

7.  A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.

Authors:  Rajesh Ringe; Deepak Sharma; Susan Zolla-Pazner; Sanjay Phogat; Arun Risbud; Madhuri Thakar; Ramesh Paranjape; Jayanta Bhattacharya
Journal:  Virology       Date:  2011-08-17       Impact factor: 3.616

8.  Analysis of HIV quasispecies suggests compartmentalization in the liver.

Authors:  Patricia K Penton; Jason T Blackard
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

9.  First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Authors:  Lindsey R Baden; Stephen R Walsh; Michael S Seaman; Yehuda Z Cohen; Jennifer A Johnson; J Humberto Licona; Rachel D Filter; Jane A Kleinjan; Jon A Gothing; Julia Jennings; Lauren Peter; Joseph Nkolola; Peter Abbink; Erica N Borducchi; Marinela Kirilova; Kathryn E Stephenson; Poonam Pegu; Michael A Eller; Hung V Trinh; Mangala Rao; Julie A Ake; Michal Sarnecki; Steven Nijs; Katleen Callewaert; Hanneke Schuitemaker; Jenny Hendriks; Maria G Pau; Frank Tomaka; Bette T Korber; Galit Alter; Raphael Dolin; Patricia L Earl; Bernard Moss; Nelson L Michael; Merlin L Robb; Dan H Barouch
Journal:  J Infect Dis       Date:  2018-07-13       Impact factor: 5.226

Review 10.  Antigenic Variation and Immune Escape in the MTBC.

Authors:  Joel D Ernst
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.